bioMerieux sees growth restrained by competition:
This article was originally published in Clinica
With competition heating up, particularly in the $700m global haemostasis market, bioMerieux achieved modest sales growth in 2004. Revenues rose by 1.8% (5.2% excluding currency effects) to E931m ($1.2bn), with the strongest sales growth in Latin America and India and molecular biology. 85% of sales were of reagents. Fourth-quarter revenues totalled E243m, up 1.2% (4.2% at constant exchange rates). Meanwhile, the Marcy l'Etoile, France-based group has exercised an option to develop RNA-based diagnostics under its recent agreement with Gen-Probe.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.